eflornithine has been researched along with Condition, Preneoplastic in 17 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although tamoxifen appears to markedly reduce breast cancer risk in women with a prior diagnosis of atypical hyperplasia or in situ carcinoma, it is not clear what other groups of women receive substantial benefit." | 8.81 | Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. ( Fabian, CJ; Kimler, BF, 2001) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 5.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Although tamoxifen appears to markedly reduce breast cancer risk in women with a prior diagnosis of atypical hyperplasia or in situ carcinoma, it is not clear what other groups of women receive substantial benefit." | 4.81 | Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. ( Fabian, CJ; Kimler, BF, 2001) |
| "Recent clinical cancer chemoprevention trials, using dose de-escalation designs, indicate that DFMO can be given over long periods of time at low doses that suppress polyamine contents in gastrointestinal and other epithelial tissues but cause no detectable hearing loss or other side effects." | 2.40 | Development of difluoromethylornithine (DFMO) as a chemoprevention agent. ( Gerner, EW; Meyskens, FL, 1999) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 1.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Patients with Barrett's esophagus (BE) and dysplasia are candidates for chemopreventive strategies to reduce cancer risk." | 1.37 | Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. ( Broaddus, R; Gerner, E; Half, E; Hong, WK; Joshi, N; Kirsch, I; Lewin, J; Morlan, B; Sinicrope, FA, 2011) |
| " However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates." | 1.31 | 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001) |
| "The dose-response relationship in male F344 rats was determined for the ability of aspirin administered in the diet to prevent azoxymethane (AOM)-induced colon cancer and aberrant crypt foci (ACF) and to reduce prostaglandin E2 (PGE2) levels." | 1.30 | Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. ( Conran, P; Hawk, EE; Kelloff, GJ; Kramer, PM; Li, H; Lubet, RA; Pereira, MA; Schut, HA; Steele, VE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pommergaard, HC | 1 |
| Burcharth, J | 1 |
| Rosenberg, J | 1 |
| Raskov, H | 1 |
| Yachimski, P | 1 |
| Peek, RM | 1 |
| Sinicrope, FA | 1 |
| Broaddus, R | 1 |
| Joshi, N | 1 |
| Gerner, E | 1 |
| Half, E | 1 |
| Kirsch, I | 1 |
| Lewin, J | 1 |
| Morlan, B | 1 |
| Hong, WK | 1 |
| Laukaitis, CM | 1 |
| Gerner, EW | 2 |
| Souza, RF | 1 |
| Spechler, SJ | 1 |
| Ranger-Moore, J | 1 |
| Alberts, DS | 1 |
| Montironi, R | 1 |
| Garcia, F | 1 |
| Davis, J | 1 |
| Frank, D | 1 |
| Brewer, M | 1 |
| Mariuzzi, GM | 1 |
| Bartels, HG | 1 |
| Bartels, PH | 1 |
| Kojima, T | 2 |
| Tanaka, T | 2 |
| Kawamori, T | 1 |
| Hara, A | 2 |
| Mori, H | 2 |
| Sawada, H | 1 |
| Mitsunaga, S | 1 |
| Clapper, M | 1 |
| Litwin, S | 1 |
| Watts, P | 1 |
| Bauer, B | 1 |
| Klein-Szanto, AJ | 1 |
| Li, H | 1 |
| Schut, HA | 1 |
| Conran, P | 1 |
| Kramer, PM | 1 |
| Lubet, RA | 1 |
| Steele, VE | 1 |
| Hawk, EE | 1 |
| Kelloff, GJ | 1 |
| Pereira, MA | 2 |
| Meyskens, FL | 1 |
| Arbeit, JM | 1 |
| Riley, RR | 1 |
| Huey, B | 1 |
| Porter, C | 1 |
| Kelloff, G | 2 |
| Lubet, R | 2 |
| Ward, JM | 1 |
| Pinkel, D | 1 |
| Krishnan, K | 1 |
| Ruffin, MT | 1 |
| Brenner, DE | 1 |
| Green, JE | 1 |
| Shibata, MA | 1 |
| Shibata, E | 1 |
| Moon, RC | 1 |
| Anver, MR | 1 |
| Fabian, CJ | 1 |
| Kimler, BF | 1 |
| Garewal, HS | 1 |
| Khoury, MD | 1 |
6 reviews available for eflornithine and Condition, Preneoplastic
| Article | Year |
|---|---|
DFMO: targeted risk reduction therapy for colorectal neoplasia.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Chemoprevention; Colorectal Neoplasms; Eflornithine; Enzy | 2011 |
Barrett's esophagus: chemoprevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Barrett Esophagus; Cyclooxygenase Inhibi | 2003 |
Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cell Division; Cell Trans | 1999 |
Chemoprevention for colorectal cancer.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidants; Ap | 2000 |
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breas | 2001 |
Chemoprevention of Barrett's esophagus and oral leukoplakia.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Barrett Esophagus; Biomarkers; Carcinoma, Squamous Cell; Ca | 1992 |
1 trial available for eflornithine and Condition, Preneoplastic
| Article | Year |
|---|---|
Chemoprevention of Barrett's esophagus and oral leukoplakia.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Barrett Esophagus; Biomarkers; Carcinoma, Squamous Cell; Ca | 1992 |
11 other studies available for eflornithine and Condition, Preneoplastic
| Article | Year |
|---|---|
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; D | 2013 |
Biomarkers in exploring the frontiers of diagnosis, prognosis, and therapy of Barrett's esophagus.
Topics: Antineoplastic Agents; Barrett Esophagus; Biomarkers, Tumor; Eflornithine; Female; Humans; Male; Muc | 2011 |
Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia.
Topics: Aged; Antineoplastic Agents; Barrett Esophagus; Eflornithine; Female; Humans; Male; Middle Aged; Muc | 2011 |
Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Disease Progression; | 2005 |
Chemopreventive effects of dietary D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, on initiation and postinitiation stages of diethylnitrosamine-induced rat hepatocarcinogenesis.
Topics: Animals; Diethylnitrosamine; Drug Screening Assays, Antitumor; Eflornithine; Glutathione Transferase | 1993 |
Chemoprevention of oral carcinogenesis by DL-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue neoplasms in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Carcinoma; Dose-Response Relationship, Drug; Drug Screening Assay | 1993 |
Chemopreventive effect of difluoromethylornithine (DFMO) on mouse skin squamous cell carcinomas induced by benzo(a)pyrene.
Topics: Animals; Benzo(a)pyrene; Carcinogens; Carcinoma, Squamous Cell; Eflornithine; Female; Hyperplasia; M | 1997 |
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon.
Topics: Animals; Aspirin; Azoxymethane; Colon; Colonic Neoplasms; Dinoprostone; Dose-Response Relationship, | 1999 |
Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Disease Progressio | 1999 |
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Cell Division; Deh | 2001 |
Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon.
Topics: Acetylcysteine; Allyl Compounds; Animals; Anticarcinogenic Agents; Azoxymethane; Colon; Colonic Neop | 1991 |